Drug intelligence / Profile preview

Bone marrow-derived mononuclear cells (BMMNCs) + Granulocyte-colony stimulating factor (G-CSF) Combination Therapy

Development stage
Unknown
Modality
Cell Therapies, Hormones & Growth Factors → Recombinant Proteins and Enzymes
Administration
Intracoronary Injection
01

Overview

Bone marrow-derived mononuclear cells (BMMNCs) + granulocyte-colony stimulating factor (G-CSF) is a combination therapy approach used primarily in regenerative medicine. This treatment involves two key components: 1. **G-CSF Administration**: G-CSF is administered to mobilize stem cells from the bone marrow into peripheral circulation. It works by triggering cell changes within bone marrow, stimulating the production of neutrophils and other stem cells, and releasing them into the bloodstream[2][3]. 2. **BMMNC Collection and Transplantation**: Following G-CSF administration, bone marrow-derived mononuclear cells are harvested (typically via bone marrow aspiration), processed, and then administered to the patient, often through intracoronary injection or other targeted delivery methods[7][10]. The combination therapy has been investigated for various conditions, particularly cardiovascular diseases like myocardial infarction and dilated cardiomyopathy, as well as ischemic conditions and neurological disorders[3][4][6][7].

Other names
BMMNC + G-CSF
02

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on Bone marrow-derived mononuclear cells (BMMNCs) + Granulocyte-colony stimulating factor (G-CSF) Combination Therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bone marrow-derived mononuclear cells (BMMNCs) + Granulocyte-colony stimulating factor (G-CSF) Combination Therapy.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call